Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Diamyd Medical ABDYMDF 41 Quick Ratio is 15.50 as of May. 2026, which is 117% above its 10-year median of 7.14. GuruFocus rates DYMDF with a GF Score™ of 41/100 and a GF Value™ of $9.89. The stock has 3 warning signs investors should review. Among 1,405 Biotechnology companies, Diamyd Medical AB ranks better than 87.54% on this metric.
Diamyd Medical AB (OTCPK:DYMDF) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Diamyd Medical AB Quick Ratio Related Terms
Diamyd Medical AB Quick Ratio Historical Data
* Premium members only.
The historical data trend for Diamyd Medical AB's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Diamyd Medical AB's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diamyd Medical AB Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Diamyd Medical AB's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Diamyd Medical AB's Quick Ratio for the fiscal year that ended in Aug. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diamyd Medical AB (DYMDF) has a Quick Ratio of 15.50 as of May. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Diamyd Medical AB and its competitors. This is 117% above median its historical median of 7.14. Over the past decade, Diamyd Medical AB's Quick Ratio has ranged from 1.53 to 16.48. According to the industry distribution chart, Diamyd Medical AB ranks #175 out of 1405 companies in the Biotechnology industry, placing it in the top 12.5%.
Is Diamyd Medical AB's Quick Ratio too high?
Diamyd Medical AB's current Quick Ratio of 15.50 is 117% above median its 10-year median of 7.14. Over the past 10 years, this metric has ranged from a low of 1.53 to a high of 16.48. The Biotechnology industry median Quick Ratio is 3.50. Diamyd Medical AB's value of 15.50 is 342.9% above this industry median. Based on the distribution chart, Diamyd Medical AB ranks #175 out of 1405 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Diamyd Medical AB has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Diamyd Medical AB's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Diamyd Medical AB ranks #175 out of 1405 companies for Quick Ratio. This places Diamyd Medical AB in the top 13% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.50. Diamyd Medical AB's value of 15.50 is 342.9% above this benchmark. Historically, Diamyd Medical AB's own Quick Ratio has ranged from 1.53 to 16.48 over the past decade. While the company's 10-year median is 7.14 vs. the industry median of 3.50, Diamyd Medical AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.50, based on 1,405 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diamyd Medical AB's current Quick Ratio of 15.50 is 342.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Diamyd Medical AB and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diamyd Medical AB's current Quick Ratio is 15.50, which is 117% above median its own 10-year median of 7.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamyd Medical AB stock overvalued right now?
Diamyd Medical AB (DYMDF) has a current Quick Ratio of 15.50. The stock's GF Value™ is $9.89, compared to a current price of $0.73 — trading 92.6% below its estimated fair value. The current Quick Ratio is 15.50, which is 117% above median its 10-year median of 7.14 and 342.9% above the Biotechnology industry median of 3.50. Diamyd Medical AB's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Diamyd Medical AB (DYMDF), the current Quick Ratio is 15.50 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diamyd Medical AB (DYMDF) Overvalued in 2026?
Based on GuruFocus' analysis, Diamyd Medical AB stock appears to be undervalued.
The current stock price of $0.73 is trading 92.6% below its estimated GF Value™ of $9.89.
Key valuation signals for DYMDF:
Quick Ratio: 15.50 (117% above median its 10-year median of 7.14)
GF Value™: $9.89 vs. price of $0.73 (92.6% below fair value)
Industry Position: 342.9% above the Biotechnology median (#175 of 1405)
No single metric tells the full story. See the DYMDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company's activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
41GF Score
Get the complete analysis for DYMDF
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DYMDF has been successfully added to your 
